Impaired cholesterol homeostasis is a major factor contributing to the development and progression of atherosclerosis. Previous studies have shown that metformin, the first-line antidiabetic therapy, has cardioprotective effects in diabetic patients. However, the anti-atherogenic effect of metformin in non-diabetic individuals remains unclear. The aim of this study was to determine the anti-atherosclerotic effects of metformin under normoglycemic conditions and, mechanistically, to assess its impact on hematopoietic stem and progenitor cell (HSPC) biology and extramedullary myelopoiesis. Here, we demonstrated that metformin decreased atherosclerotic lesion size, reduced plaque macrophages, and lowered circulating atherogenic Ly6-C^hi monocytes and neutrophil levels in <i>Apoe^-/-</i> mice, independent of blood glucose regulation. Mechanistically, metformin-treated <i>Apoe^-/-</i> mice exhibited increased HSPC retention in the bone marrow and decreased numbers of circulating HSPCs, along with reduced levels of Ly6-C^hi monocytes and neutrophils in the spleen. Our results indicate that decreased circulating cholesterol and increased expression of the ATP-binding cassette (ABC) transporter gene <i>Abca1</i> in HSPCs, thereby promoting cholesterol efflux in these cells, are critical factors leading to the suppressed mobilization of HSPCs and myelopoiesis in metformin-treated mice. Collectively, our findings support the use of metformin as an anti-atherosclerotic agent under euglycemic conditions. We reveal that this effect is achieved by dampening HSPC mobilization and extramedullary myelopoiesis, providing molecular evidence for metformin's role in reducing macrophage-driven inflammation and, consequently, attenuating atherosclerotic progression.